Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1148-1152

  Aladdin, Hassan ^a   Ullum, Henrik ^a   Nielsen, Susanne Dam ^b   Espersen, Christina ^a   Mathiesen, Lars ^b   Katzenstein, Terese L ^a   Gerstoft, Jan ^a   Skinhoj, Peter ^a   Pedersen, Bente Klarlund ^a  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

EID: 0034113954     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315305     Document Type: Article

References (13)

1. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
2. 2. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
3. 3. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998;280: 72-7.
4. 4. Ullum H, Katzenstein T, Aladdin H, et al. Immunological changes in human immunodeficiency virus (HIV) infected individuals during HIV-specific protease inhibitor treatment. Scand J Immunol 1999;49:539-47.
5. 5. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29.
6. 6. Nielsen SD, Afzelius P, Dam-Larsen S, et al. Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy. J Infect Dis 1998;177:1733-6.
7. 7. Hartung T, Pitrak DL, Foote M, Shatzen EM, Verral SC, Wendel A. Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection. J Infect Dis 1998;178: 686-92.
8. 8. Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. AIDS 1996;10:1627-33.
9. 9. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 1998;12:65-74.
10. 10. Tvede N, Pedersen BK, Hansen FR, et al. Effect of physical exercise on blood mononuclear cell subpopulations and in vitro proliferative responses. Scand J Immunol 1989;29:383-9.
11. 11. Akbar AN, Salmon M, Janossy G. The synergy between naive and memory T cells during activation. Immunol Today 1991;12:184-8.
12. 12. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Dene Syndr 1991;4:11-23.
13. 13. Hartung T, Docke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995;85:2482-9.